Progress and pitfalls of chimeric antigen receptor T cell immunotherapy against T cell malignancies.
Chimeric antigen receptor T cell (CAR-T) immunotherapy has revolutionized the treatment of relapsed and refractory B cell-derived hematological malignancies. Currently, there are six FDA-app...